NasdaqCM - Nasdaq Real Time Price • USD
Exact Sciences Corporation (EXAS)
As of 3:09 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 16 | 16 | 15 | 17 |
| Avg. Estimate | -0.3 | -0.14 | -1.12 | -0.08 |
| Low Estimate | -0.44 | -0.28 | -1.43 | -0.7 |
| High Estimate | -0.13 | 0.03 | -0.56 | 0.49 |
| Year Ago EPS | -0.45 | 0 | -1.13 | -1.12 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 20 | 20 | 19 | 19 |
| Avg. Estimate | 688.69M | 731.23M | 2.83B | 3.22B |
| Low Estimate | 638M | 712.1M | 2.82B | 3.16B |
| High Estimate | 702.56M | 742M | 2.84B | 3.31B |
| Year Ago Sales | 622.09M | 616.81M | 2.5B | 2.83B |
| Sales Growth (year/est) | 10.70% | 18.60% | 13.30% | 13.80% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.51 | -0.48 | -0.46 | -0.47 |
| EPS Actual | -0.45 | 0 | -0.27 | -0.6 |
| Difference | 0.06 | 0.48 | 0.19 | -0.13 |
| Surprise % | 11.80% | 100.00% | 41.30% | -27.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.3 | -0.14 | -1.12 | -0.08 |
| 7 Days Ago | -0.29 | -0.14 | -1.08 | -0.05 |
| 30 Days Ago | -0.23 | -0.11 | -0.85 | 0.06 |
| 60 Days Ago | -0.22 | -0.11 | -0.83 | 0.07 |
| 90 Days Ago | -0.25 | -0.19 | -0.99 | 0.09 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 2 | -- | 3 |
| Up Last 30 Days | 3 | 5 | 2 | 4 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 4 | 3 | 5 | 2 |
Growth Estimates
| CURRENCY IN USD | EXAS | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 33.30% | -- | -- | 8.00% |
| Next Qtr. | -- | -- | -- | 12.40% |
| Current Year | 0.90% | -- | -- | 5.60% |
| Next Year | 92.90% | -- | -- | 12.60% |
| Next 5 Years (per annum) | 98.50% | -- | -- | 11.14% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | BTIG: Buy to Buy | 5/9/2024 |
| Maintains | Canaccord Genuity: Buy to Buy | 5/9/2024 |
| Maintains | Citigroup: Buy to Buy | 5/9/2024 |
| Maintains | Citigroup: Buy to Buy | 4/3/2024 |
| Maintains | Canaccord Genuity: Buy to Buy | 2/22/2024 |
| Upgrade | Benchmark: Hold to Buy | 1/2/2024 |
Related Tickers
GH Guardant Health, Inc.
24.84
-2.05%
ILMN Illumina, Inc.
108.66
-2.17%
TWST Twist Bioscience Corporation
45.26
-3.72%
NTRA Natera, Inc.
106.58
+0.11%
CDNA CareDx, Inc
15.60
+0.65%
TMO Thermo Fisher Scientific Inc.
594.24
-0.18%
DHR Danaher Corporation
267.02
+0.46%
VCYT Veracyte, Inc.
22.29
-2.58%
CRL Charles River Laboratories International, Inc.
222.42
+0.37%
DGX Quest Diagnostics Incorporated
144.72
+0.26%